PeptideTreatments
Reviewed by Peptide Treatments Medical Advisory Board

Dihexa: Research & Evidence

Early-Stage Research

Published research, clinical trial data, and evidence grading for Dihexa across studied indications.

Back to Dihexa overview

Research Summary

Dihexa has zero completed human clinical trials. The derivative fosgonimeton (ATH-1017) failed a Phase 3 Alzheimer's trial (LIFT-AD, N=312) in September 2024. All efficacy data comes from rodent studies. The '10 million times more potent than BDNF' claim is based on in vitro enzyme assays, not human cognitive data.

Evidence by Indication (2 indications)

Indication Tier Trials Summary
Cognitive enhancement Tier D 0 Preclinical only — potent HGF/c-Met activator in animal models of cognitive decline
Neuroprotection Tier D 0 Animal studies show synaptogenesis promotion; no human trials conducted

Graded using our evidence tier methodology.

Research Gap Score /10

Higher score = larger gap between therapeutic potential and available clinical evidence.

Citations (10 sources)

  1. 1. Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats. Study

    (2024), Journal of Huntington's disease

  2. 2. Efficiently generate functional hepatic cells from human pluripotent stem cells by complete small-molecule strategy. Study

    (2022), Stem cell research & therapy

  3. 3. AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway. Study

    (2021), Brain sciences

  4. 4. Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies. Review

    (2018), Neuroscience and biobehavioral reviews

  5. 5. The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases. Study

    (2015), Progress in neurobiology

  6. 6. Hepatocyte growth factor mimetic protects lateral line hair cells from aminoglycoside exposure. Study

    (2015), Frontiers in cellular neuroscience

  7. 7. The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease. Study

    (2015), Journal of Alzheimer's disease : JAD

  8. 8. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system. Study

    (2014), The Journal of pharmacology and experimental therapeutics

  9. 9. Effect of structure on the interactions between five natural antimicrobial compounds and phospholipids of bacterial cell membrane on model monolayers. Study

    (2014), Molecules (Basel, Switzerland)

  10. 10. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. Study

    (2013), The Journal of pharmacology and experimental therapeutics